Table 1 The approved immune checkpoint inhibitors in the globe
From: Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Target | Active Ingredients | First approval time | Company | Application(approved in the globe) |
|---|---|---|---|---|
PD-1 | Nivolumab | 2014 | Bristol Myers Squibb | Melanoma, NSCLC, MPM, RCC, HL HNSCC, UC, CRC, HCC, Esophageal Cancer, GC, GEJC, EA |
Pembrolizumab | 2014 | Merck Sharp Dohme | Melanoma, NSCLC, HNSCC, HL, PMBCL, UC, CRC, GC, Esophageal cancer, CC, HCC, MCC, RCC, Endometrial carcinoma, CSCC, TNBC | |
Cemiplimab | 2018 | Regeneron Pharmaceuticals | CSCC, BCC, NSCLC | |
Toripalimab | 2018 | Shanghai Junshi Biosciences Co., Ltd. | Melanoma, UC, NPC, ESCC | |
Sintilimab | 2018 | Innovent Biologics, Inc | NSCLC, HL, HCC, ESCC, GC, GEJC | |
Camrelizumab | 2019 | Jiangsu Hengrui Medicine Co.,Ltd. | NSCLC, HL, HCC, ESCC, NPC | |
Tislelizumab | 2019 | Beigene, Ltd. | NSCLC, HL, UC, HCC, NPC, ESCC, CRC | |
Zimberelimab | 2021 | Guangzhou Gloria Biosciences Co., Ltd. | HL | |
Prolgolimab | 2020 | Biocad. | Melanoma, SC | |
Dostarlimab | 2021 | GSK Plc | Endometrial carcinoma | |
PD-L1 | Atezolizumab | 2016 | Genetech Inc | Melanoma, NSCLC, SCLC, HCC, ASPS |
Durvalumab | 2017 | AstraZeneca | NSCLC, ES-SCLC, BTC, HCC | |
Avelumab | 2017 | EMD Serono Inc | UC, MCC, RCC | |
CTLA-4 | Ipilimumab | 2011 | Bristol Myers Squibb | Melanoma, RCC, CRC, HCC, NSCLC, MPM, Esophageal cancer |